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a b s t r a c t
Objective: The aim of this study was to describe the most frequently found bacterial microor-
ganisms in bloodstream isolates taken from patients in intensive care units in Colombia and
their resistance proﬁles.
Methods: This was a multicentre descriptive observational study that was carried out
between January 2001 and June 2008 with laboratory data from 33 participating hospitals in
a surveillance network.
Results: The most frequently found microorganisms were coagulase-negative Staphylococci
39.6%, Staphylococcus aureus 12.3%, Klebsiella pneumoniae 8.2%, Escherichia coli 5.7%, Acineto-
bacter baumannii, 4.0% and Pseudomonas aeruginosa 3.8%. Coagulase-negative Staphylococci
registered greater than 70% oxacillin resistance rate. S. aureus presented a change in its
multiresistance proﬁle during the years of follow-up. There was a trend towards a lower
resistance rate among E. coli and K. pneumoniae isolates during the study period while A.
baumannii carbapenem resistance rate exceeded 50%.Discussion: There has been a change in the frequency of species being isolated with a higher
frequency of enterobacteriaceae compared to Gram-positive microorganisms, in general
with a high resistance rate.
costs associated with health care. According to the World
13 EIntroduction
© 20Bacteremia acquired in the hospital is a frequent cause of
morbidity and mortality in intensive care units (ICU)],1 having
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Health Organization (WHO), 8.7% of hospital acquired infec-
tions correspond to bacteremia2 and retrospective studies
have shown that the incidence of nosocomial bacteremia is
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Fig. 1 – Frequency of selected Gram-positive cocci
associated with bloodstream infections in patients in
intensive care units, excluding coagulase negativebraz j infect d i s .
lose to six episodes per 1000 hospital admissions. ICU ranks
rst amongst hospital services (51% of events) followed by
dult internal medicine services (38%), surgical services (20%)
nd paediatric rooms (13.5%).1,2 It has been reported that ICU
atients present a greater tendency for developing episodes
f nosocomial bacteremia compared to those admitted to
ifferent hospital wards.3 This is related to patients’ suscepti-
ility due to immunosuppression and frequent use of invasive
evices, suchas intravascular andurinary catheters, and tubes
or supporting mechanical ventilation.3
Knowing the most frequent pathogenic microorganisms
hat colonise or infect this type of patient allow for effective
mpirical antibiotic treatment taking into account microor-
anisms’ susceptibility and resistance patterns. A general
ncrease in bacterial resistance rates has been reported around
he world, giving rise to multiresistant strains within hospi-
als and thereby generating serious problems for health-care
nstitutions.2,3 There have been reports of resistance of sev-
ral important pathogens in the hospital setting, such as
taphylococcus aureus, coagulase-negative Staphylococcus (CNS),
nterococcus spp., Escherichia coli, Klebsiella pneumoniae and non-
ermenting enterobacteria, such as Pseudomonas aeruginosa
nd Acinetobacter baumannii.2
This study describes the frequency and resistance patterns
f microorganisms associated with bacteremia presented in
ritically ill patients in ICUs of a third-level hospital network
n Colombia.
aterials and methods
esign
his was a descriptive, observational study, based on multi-
entre surveillance of bacterial isolates from blood samples
aken from patients admitted to ICU belonging to the Bogotá
acterial Resistance Control Group’s (GREBO – Grupo para el
ontrol de la Resistencia Bacteriana de Bogotá) surveillance system
rom January 2001 to June 2008.
urveillance network
his network consists of thirty-three institutional laboratories
f third-level hospitals (hospital capacity ranging from 100 to
00 beds), located in ﬁve regions of Colombia: Bogotá (capi-
al city of Colombia), Ibagué and Neiva (Southwest part of the
ountry), Manizales (mountainous area adjacent to the coffee
rowing area) and Cúcuta (near the border with Venezuela).
he surveillance network started with 12 institutions that
ave common procedures for detecting resistance, reporting
t, and centralized quality control.4
All institutions have automated identiﬁcation and bac-
erial susceptibility test systems (MicroScan, Dade Behring,
SA or Vitek, Biomerieux, France) and are run in line
ith the 2007 Clinical and Laboratory Standard Institute
CLSI) guidelines.5 Criteria for blood sampling was decided
ndividually upon the discretion of the assistant physi-
ian in all participating ICU. The number of samples and
he blood volume taken were decided by each institutional
rotocol.Staphylococci. 2001–ﬁrst half of 2008.
Analysis
Each institution collected information monthly in databases
exported from automated systems. Each database converted
to a standard format usingBaclink 2.0 software (WHO, Switzer-
land) and then analysed using Whonet 5.4 software (WHO,
Switzerland).6 Results of blood cultures collected at services
identiﬁed as ICU were extracted for analysis. Only the ﬁrst
positive blood culture of each patient was included in the
analysis. Annual absolute and relative resistance frequen-
cies were analysed. Comparative tables, tendency plots, and
histograms were prepared in Excel 2007 software (Microsoft,
USA). Resistant markers were chosen for the most commonly
foundmicroorganisms: oxacillinwas chosen for staphylococci
resistance, third generation cephalosporins for Gram-negative
enteric bacilli, ceftazidime for P. aeruginosa, imipenen for A.
baumannii, and vancomycin for Enterococcus faecalis.
Results
Thehospital network reported 21,183 isolates fromblood sam-
ples of patients admitted to their ICUs from January 2001 to
June 2008. An annual increase in the number of isolates was
observed, from 1175 in 2001 to 5069 in 2007. Such an increase
was sustained in 2008, when 2437 isolates being recorded in
just the ﬁrst half of the year. This annual incremental trend
was maintained after standardizing for the number of isolates
per number of hospitals in each period (Table 1).
Microorganism frequency
Table 2 describes the 10 microorganisms more frequently iso-
lated in order of frequency in the network ICU.
From 2001 to 2007, the rates of positive blood cultures
for coagulase negative Staphylococci (CNS) were 41%, 39%,
40%, 41%, 39%, 39% and 36%, respectively; a rate of 40% was
recorded for the ﬁrst half of 2008. Fig. 1 describes the annual
relative frequency pattern for other Gram-positive microor-
ganisms isolated from blood in the ICUs (S. aureus and E.
348 braz j infect d i s . 2013;17(3):346–352
Table 1 – Frequency of isolated microorganisms standardized by year. 2001–ﬁrst half of 2008.
Year Number of
isolates (n)
Number of
hospitals
Total months
notiﬁed
Average months
notiﬁed
Average of isolates per
month per hospital
2001 1176 12 127 10.6 9.3
2002 1942 13 142 10.9 13.7
2003 1841 16 188 11.8 9.8
2004 2788 19 216 11.4 12.9
2005 2959 22 262 11.9 11.3
2006 3420 22 258 11.7 13.3
2007 5070 28 326
2008 2438 33 197
Table 2 – Most frequently isolated microorganisms from
bloodstream infections in patients in the ICU, 2001–ﬁrst
half of 2008.
Microorganism Number
of isolates
(%)
Coagulase-negative Staphylococcus 8384 39.6%
Staphylococcus aureus 2615 12.3%
Klebsiella pneumoniae 1727 8.2%
Escherichia coli 1208 5.7%
Acinetobacter baumannii 840 4.0%
Pseudomonas aeruginosa 814 3.8%
Enterobacter cloacae 718 3.4%
Enterococcus faecalis 616 2.9%
pathogenic bacteria has been observed during the last fewSerratia marcescens 542 2.6%
Klebsiella oxytoca 309 1.5%
faecalis). Fig. 2 shows the pattern for some Gram-negative
bacilli selected by frequency and their pathogenic potential.
Antimicrobial resistance
Table 3 summarizes the frequencies of resistance for selected
markers of resistance among microorganisms isolated from
blood at the participating ICUs per year. Reduced rates of
oxacillin resistance of S. aureus and a change in multire-
sistance proﬁle were seen (Fig. 3), as well as recovery of K.
pneumoniae susceptibility to third-generation cephalosporins.
A. baumannii presented a ﬁvefold increase in its rate of initial
resistance to carbapenems, rising from 10.5% in 2001 to 49.5%
in the ﬁrst half of 2008.
E. faecalis vancomycin resistance rates did not exceed 4%
and were recorded in some institutions of the network. Such
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increase was not sustained in the following years. A marked
reduction in proven high-level gentamicin resistance was
simultaneously recorded for this microorganism, falling from
25% in 2001 and 2002 to less than 13% resistance rate from
2005 to 2007. Close to 3% carbapenem resistance was reported
in K. pneumoniae isolates during the last two years of observa-
tion. The rate of ciproﬂoxacin-resistant E. coli ranged from 20%
to 30% for isolates taken from blood during the observation
period.
P. aeruginosa presented resistance to several antimicrobial
drugs, varying from 15% to 30% during the observation period
for isolates taken from blood (Fig. 4).
A. baumannii showed greater resistance to multiple antibi-
otics, ranging from 35% to 60% in the follow-up period. An
overall increase of resistance to carbapenems of this microor-
ganism was recorded, reaching rates higher than 50% (Fig. 5).
Discussion
The widespread distribution of resistant Gram-positive and
Gram-negative microorganisms to currently available antimi-
crobial drugs has gained importance in Europe, NorthAmerica
and Latin-America.7 Reports in our setting have shown the
widespread participation of multiresistant microorganisms in
bacteremia of patients admitted to ICUs.8,9
A rapid frequency increase in multiple-antibiotic-resistantyears7 with a change in the expected distribution of differ-
ent markers. In spite of the high frequency of isolates for
CNS and S. aureus, the frequency and participation of other
2006
= 3420
2007
n = 5707
2008
n = 2438
K. pneumoniae
E. coli
A. baumannii
P. aeruginosa
E. cloacae
ith bloodstream infections in patients admitted to ICU.
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Table 3 – Resistance markers for most frequently isolated microorganisms from bloodstream infections in patients in
ICU. 2001–ﬁrst half of 2008.
Marker 2001 2002 2003 2004 2005 2006 2007 2008
n % n % n % n % n % n % n % n %
Oxacillin-resistant
CNS
253 90.5 245 84.1 236 76.4 346 80.6 594 85.2 710 84.5 1113 84.8 517 78.5
Oxacillin-resistant S.
aureus
146 62.3 244 63.5 296 64.9 341 58.1 369 47.2 391 43 533 43.3 216 33.4
Third-generation
Cephalosporin-
resistant K.
pneumoniae
53 58.5 89 58.4 99 35.4 190 35.3 207 28 287 26.8 397 26.2 240 17.9
Third-generation
cephalosporin-
resistant
E. coli
46 6.5 59 15.3 82 8.5 128 5.5 151 6.6 181 7.2 262 8.8 145 4.8
Imipenem-resistant A.
baumannii
57 10.5 68 27.9 56 37.5 72 41.7 105 55.2 139 42.4 211 54.5 99 49.5
Cephthazidim-
resistant P.
aeruginosa
56 28.6 47 40.4 64 15.6 80 20 99 30.3 142 28.2 177 39 99 29.3
Third-generation
Cephalosporin-
resistant E.
cloacae
39 33.3 42 40.5 41 36.6 73 17.8 93 25.8 102 29.4 154 26 77 16.9
Vancomycin-resistant
E. faecalis
54 1.9 42 2.4 64 0 77 3.9 81 0 103 1.9 118 0 55 0
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ram-negative bacteria (i.e. K. pneumoniae and E. coli) have
ncreased in ICU-related bacteraemia.10,11
The percentage of pathogens isolated from blood in our
tudy was similar to the results reported in 2008 by Hidron
t al., in a hospital network reporting to CDC.12 Differ-
nt authors have reported these microorganisms as being
he most frequently occurring agents causing ICU service-
cquired infections.7,13 The clinical importance of CNS as
ausal agent in our setting is beyond the scope of this report;
owever, its participation should be stressed in some popu-
ations at risk, especially in those with infections related to
he use of external devices.14 High levels of oxacillin-resistant
NS were observed, a frequent ﬁnding in our region, since
t has been described that around 80% of CNS isolates in
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Latin-America are oxacillin resistant.15 One of the greatest
problem observed in laboratory system-based surveillance
is to discriminate CNS pathogenic strains from contami-
nant strains (normal skin ﬂora); this represents a challenge
since CNS has been reported as being the microorganism
most commonly causing contamination in microbiological
cultures.14 Such high rate of contamination could be related to
deﬁcient cleaning practice amongst medical personnel, ster-
ilizing instruments and surgical areas, thereby increasing the
risk of pathogen dissemination and acquiring post-operation
infection.16The second microorganism in importance was S. aureus,
for which a reduction in the frequency in ICUs was observed,
simultaneouslywith a change inmultiresistance proﬁle. Some
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authors have previously reported such change8 and it has
been proposed to be inﬂuenced by hospital clones being dis-
placedbyan increase in circulating community-derived clones
having a multisensitivity pattern.11,17 These clones’ partici-
pation has been identiﬁed in Colombia, North America and
some Latin-American countries. A molecular study carried
out in 2008 by Arias et al. described similarities in the pat-
tern of strains circulating in Colombia and the USA; this
reinforced the need for establishing public health action in
health care centres due to the risk of crossed dissemination
in hospital services of such resistant strain coming from the
community.18
A change in the frequencyof predominatingGram-negative
was observed during the study period. Up to 100% increases
were recorded when compared to the Gram-positive pattern;
K. pneumoniae, E. coli and S. marcescens had similar increases to
those reported in other studies.10 Enterobacteriaceae partic-
ipation in the ICU setting and their increase have important
repercussions, given its general association with the use of
mechanical ventilation and other invasive devices such as uri-
nary catheters.19
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An important reduction in resistance to third-generation
cephalosporins was recorded for K. pneumoniae, E. coli and
Enterobacter cloacae, as has been observed in other studies
of ICU patients but not among patients admitted to gen-
eral wards in Colombia.20 This could have been related
to improvement in infection control policies and bet-
ter antimicrobial use, as some broad spectrum antibiotics
have been the target for control action given their poten-
tial for inducing extended spectrum beta-lactamase (ESBL)
enzymes.21
Close to 3% carbapenem resistance has been observed
during the last two years in enterobacteria; this has been
compatible with the beginning of carbapenemase circulation
in Colombia.22 The appearance of these resistant isolates
might have to do with a change in the use of antimicrobials,
increased use of carbapenems or other antibiotics, as well as
clonal dissemination.23
There was high multiresistance rates in non-fermenting
Gram-negative bacteria. P. aeruginosa showed a clear increase
of its multiresistant phenotypes. Our results were similar to
other studies which have recorded 12.8–20.8% resistance rates
in North America, and 16.8–30% in Europe, leading to the com-
mon use of empirical combined antimicrobial therapy against
P. aeruginosa despite the recognition of the inefﬁcacy of such
approach in different scenarios.24
A. baumannii expressed a greater multiresistance pattern,
ranging from 35% to 60% in the study period. This mul-
tiresistance rates have been described in other countries,
recognizing that the rates of susceptibility pattern of iso-
lates in Latin-America are much lower than those recorded
in North America and Europe.25 A ﬁvefold increase in resis-
tance was observed in Colombia between 2001 and 2008.
Tognim et al. carried out a ﬁve-year follow-up (1997–2001) in
Latin-American countries, ﬁnding a reduction in carbapenem
susceptibility; the highest resistance rates were recorded in
Argentina (20%), followed by Colombia (14%), Brazil (8.5%) and
Chile (0.7%).26
This phenomenon has a multifactorial origin; widespread
use of carbapenems, especially in ICU services, is considered
to be the greatest risk factor for selecting high carbapenem-
resistance and could be playing an important role,27 but also
the easy dissemination of this microorganism and its ability
to acquiremultiple resistancemechanisms further complicate
the scenario.13
The importance of our results in the identiﬁcation of
highly resistant patterns among microorganisms causing
bloodstream infection, thereby leading to inadequate ini-
tial empirical therapy24; unexpected adverse results are thus
obtained, increasing the risk of mortality, length of hospital
stay andhospital costs.26 These surveillancedata are the start-
ing point for generating prevention and control measures to
tackle this alarming problem. The resistance patterns circu-
lating in given setting must be identiﬁed for determining the
most suitable therapy; one must bear in mind that the resis-
tance patterns vary between countries and between different
hospital services.4Using data based on a laboratory network’s surveillance
systems is of great utility to deﬁne isolate frequency and to
decide empirical therapy. Some limitations, such as estimat-
ing prevalence of infection-causing resistant microorganisms
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nd uniformity in processing samples must be considered
hen interpreting the information.28 However, establishing
entralized quality control and following-up standards could
elp improving the quality of information.
Results of this study of bacteremia in critically ill patients
ighlight an incremental trend in Gram-negative bacilli whilst
he relative frequency of Gram-positive cocci (S. aureus, CNS, E.
aecalis) has decreased. These microorganism resistance rates
ere high, even when compared to those identiﬁed in other
tudies in Latin America, Europe and North America. This
tudy has provided relevant information for guiding empiri-
al therapy for ICU patients and sounding an alert concerning
he need for generating strategies for controlling resistance in
ur settings.
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